The once-daily long-acting muscarinic antagonist (LAMA) tiotropium and once-daily long-acting b 2 -agonist (LABA) olodaterol have been studied as a once-daily fixed-dose combination (FDC) in patients with chronic obstructive pulmonary disease (COPD).
Two large, 52-week, double-blind, parallelgroup studies in patients with moderate-very severe COPD demonstrated that tiotropium ? olodaterol significantly improved lung function and symptoms versus the monocomponents. This post hoc analysis determined effects on lung function by prior LAMA or LABA maintenance treatment and initial disease severity.
Methods: 5162 patients were randomized and treated with olodaterol 5 lg, tiotropium 2.5 lg, tiotropium 5 lg, tiotropium ? olodaterol 2.5/ 5 lg, or tiotropium ? olodaterol 5/5 lg (all once daily via Respimat Ò inhaler). Primary efficacy (lung-function) end points were forced expiratory volume in 1 s (FEV 1 ) area under the curve from 0 to 3 h (AUC 0-3 ) and trough FEV 1 responses (i.e., change from baseline). Pooled data are presented for the following subgroups: prior maintenance treatment with LAMA or LABA, Global initiative for chronic Obstructive Lung Disease (GOLD) 2 (predicted FEV 1 50% to \80%) and 3 (30% to\50%)/4 (\30%), sex, age, and prior use of inhaled corticosteroids.
Results: Tiotropium ? olodaterol FDC improved lung function over the monocomponents in patients with GOLD 2 Electronic supplementary material The online version of this article (doi:10.1007/s12325-015-0218-0) contains supplementary material, which is available to authorized users. and 3-4 disease, irrespective of prior LAMA or LABA maintenance therapy; most comparisons between FDCs and their respective monocomponents were statistically significant (P\0.05). FEV 1 AUC 0-3 and trough FEV 1 responses for the individual treatments were generally greater in patients with less severe COPD at baseline.
Conclusions: Tiotropium ? olodaterol 5/5 lg significantly improved FEV 1 AUC 0-3 and trough FEV 1 in all GOLD severity groups compared to olodaterol 5 lg and tiotropium 5 lg alone, irrespective of whether patients had received prior LAMA or LABA maintenance treatment. Improvements from baseline in lung function were generally greater in patients with less severe disease. Funding: Boehringer Ingelheim. [1] . The once-daily LAMA tiotropium is well established in the treatment of COPD and improves the main functional and patient-orientated outcomes of the disease [2] [3] [4] [5] [6] [7] . Olodaterol is a novel oncedaily LABA that provides 24-h bronchodilation [8] [9] [10] [11] , symptomatic benefit [12] , and enhanced exercise capacity [13] . Tiotropium ? olodaterol has recently been evaluated in a phase III program to determine its efficacy in the treatment of COPD [14, 15] .
International guidelines indicate that combining bronchodilators of different pharmacologic classes may improve efficacy and reduce the risk of side effects, rather than increasing the dose of a single bronchodilator.
The introduction of combination products raises questions regarding the timing of their initiation during the course of COPD, with recent data indicating the potential benefits of earlier pharmacologic intervention with combination bronchodilator medications [16] [17] [18] [19] [20] . LAMA long-acting muscarinic antagonists, LABA long-acting b 2 -agonist, GOLD Global initiative for chronic Obstructive Lung Disease, SD standard deviation, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity a Based on post-bronchodilator FEV 1 percentage predicted included outpatients aged C40 years with a history of moderate to very severe COPD (GOLD 2-4). Key inclusion and exclusion criteria are detailed in Fig. 2 .
End Points
The primary spirometry end points were evaluated after 24 weeks of treatment as these studies have been reported previously [14] .
Statistical Methods
In this analysis, FEV 1 AUC 0-3 and trough FEV 1 were evaluated according to the following subgroups: patients without prior LAMA or LABA treatment at baseline or patients with prior LAMA or LABA treatment at baseline.
Within each category of prior LAMA/LABA use, analyses were split according to whether patients had GOLD 2 (predicted FEV 1 50% to \80%) or GOLD 3 (30% to \50%)/4 (\30%) COPD at baseline. 
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors. Tables 1 and 2 based on prior LAMA or LABA maintenance treatment for COPD and GOLD stage.
Overall baseline characteristics were similar across maintenance-treatment subgroups. Lung function in patients with GOLD 2 disease did tend to be slightly better in those who did not 
Maintenance Treatment
In each treatment group, FEV 1 AUC 0-3 responses (i.e., change from baseline) were greater in patients with GOLD 2 disease than GOLD 3-4 disease ( Fig. 3a ; Table S1 in the electronic supplementary material). In both of the GOLD subgroups, FEV 1 AUC 0-3 responses were greater with both doses of tiotropium ? olodaterol than the monotherapy components at Week 24, and differences were statistically significant for all comparisons analyzed (Table 3) . Trough FEV 1 responses were consistently greater with both doses of tiotropium ? olodaterol than the monotherapy components; no obvious trend was apparent between patients with GOLD 2 and GOLD 3-4 COPD (Fig. 4a ). While all differences between the various monotherapies and tiotropium ? olodaterol 5/5 lg were statistically significant in patients with GOLD 2 COPD, in GOLD 3-4 COPD patients receiving tiotropium ? olodaterol 2.5/5 lg the differences were not as robust, such that changes in trough FEV 1 with tiotropium 5 lg were not significantly different from tiotropium ? olodaterol 2.5/5 lg (Table 3) .
Patients Receiving Prior LAMA or LABA

Maintenance Treatment
In patients who received prior maintenance treatment, as in patients without prior LAMA or LABA maintenance bronchodilator therapy, the FEV 1 AUC 0-3 responses for the individual treatments were greater in those with less severe COPD ( Fig. 3b ; Table S2 in the electronic Trough FEV 1 responses were consistently greater with both doses of tiotropium ?
olodaterol than the monotherapy components and were generally greater in patients with less severe COPD (with the exception of tiotropium ? olodaterol 2.5/5 lg) (Fig. 4b ). All comparisons between tiotropium ? olodaterol and the monotherapies were statistically significant in patients with GOLD 3-4 COPD; Table 4 ). [23] [24] [25] . Of particular note, tiotropium ? olodaterol 5/5 lg once daily improved lung function in patients with GOLD 2 and 3-4 disease, and there were no apparently relevant differences in lung-function responses according to whether these patients had or had not received prior maintenance therapy with a LAMA or a LABA.
Other Patient Subgroups
While no statistical comparisons were made between subgroups, it was apparent that both FEV 1 AUC 0-3 and trough FEV 1 responses for the individual treatments were, in general, greater in patients with less severe disease. The greater lung-function responses observed in patients with GOLD 2 COPD in our studies are in line with other clinical trials, including the 4-year study of tiotropium (UPLIFT; NCT00144339) [18] . While patients are less symptomatic earlier in their disease course, recent data have suggested that the progression of early COPD occurs at a faster rate than during the later stages of disease [16, 17] . In addition, the UPLIFT study suggested a possible reduction in the rate of decline of post-bronchodilator FEV 1 in patients with GOLD 2 COPD using tiotropium [18] . As more information becomes lung function, and exacerbations to good maintenance bronchodilator therapy in COPD patients with less severe disease, opinion is moving towards using effective bronchodilation in the earlier stages of COPD [18, 26] .
Our data support the use of dual-action maintenance bronchodilator therapy with LAMA ? LABA for treatment-naive and less severe COPD, as well as those more severe patients already receiving maintenance therapies. Both doses of tiotropium ? olodaterol were more effective than the monotherapy components in all subgroups analyzed, although the lower dose of the combination (2.5/5 lg) may have been slightly less effective in providing trough bronchodilation in less severe, treatment-naive patients. In addition, it appeared that the FEV 1 AUC 0-3 responses were somewhat greater in younger patients than older patients, a finding that may reflect more the greater response in the less severe patients rather than a primary age effect. Otherwise, no major differences in responses were observed between treatment groups.
Our analysis does have some limitations in so far as it was post hoc and no direct statistical comparisons could be made between subgroups.
However, based on the fact that data were pooled from two large phase III studies, the 
